Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

162.55 -4.32 (-2.59%)
Streaming Delayed Price Updated: 9:35 AM EST, Mar 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
News headline image
As Investors Flee U.S. Equities, This Global ETF Is Outperforming ↗
Via MarketBeat
Topics ETFs
News headline image
Second HeLa Lawsuit Resolved As Novartis Reaches Confidential Settlement ↗
Novartis reached a confidential settlement with Henrietta Lacks' family, resolving a second lawsuit over the nonconsensual use of HeLa cells. 
Via Benzinga
Topics Lawsuit
News headline image
Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy
In a move that solidifies a new standard of care for a high-risk patient population, the U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer Inc. (NYSE: PFE) for its BRAFTOVI... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies ↗
Investors weigh steep GLP‑1 price cuts against a multibillion‑dollar oral obesity push, fresh analyst caution, and a new partnership, today, Feb. 25, 2026. 
Via The Motley Fool
Topics Stocks
Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock with Strong Fundamentals ↗
Via Chartmill
News headline image
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total... 
Via MarketMinute
Topics Intellectual Property
News headline image
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio? ↗
It has the qualities of a buy-and-forget stock. 
Via The Motley Fool
Topics Intellectual Property Retirement
News headline image
Arvinas (ARVN) Q4 2025 Earnings Call Transcript ↗
Arvinas (ARVN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Stock Market Today, Feb. 23: Novo Nordisk Plunges 16% After Obesity Drug Falls Short ↗
Today, Feb. 23, 2026, a pivotal obesity‑drug trial setback forces investors to rethink Novo Nordisk’s strategy. 
Via The Motley Fool
Topics Stocks
News headline image
Novartis: This Big Pharma Giant Could Be a Sleep‑at‑Night Core Holding for Decades ↗
Novartis has a solid portfolio of drugs and a pipeline that should keep the business humming. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer’s BRAFTOVI BREAKWATER Trial Delivers Landmark Survival Gains in Colorectal Cancer
NEW YORK — Pfizer Inc. (NYSE: PFE) has announced breakthrough results from its Phase 3 BREAKWATER clinical trial, demonstrating that its BRAFTOVI (encorafenib) regimen significantly improves both... 
Via MarketMinute
News headline image
A Look Into Novartis Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
Promethos Capital Liquidates $4 Million Sprouts Farmers Market Position: Should Investors Sell, Too? ↗
Sprouts Farmers Market runs a national grocery chain focused on fresh, natural, and organic foods for health-conscious shoppers. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Decade, According to Wall Street Analysts ↗
Goldman Sachs expects European and emerging-market equities to beat the U.S. stock market over the next decade. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Novartis Says Conditionally Approved Kidney Drug Shows Long-Term Promise ↗
Novartis shared final Phase 3 results showing Vanrafia may slow kidney function decline in adults with IgA nephropathy. 
Via Benzinga
News headline image
Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance
As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. Known as... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss
As of February 11, 2026, Incyte Corporation (NASDAQ: INCY) finds itself at a pivotal crossroads. Known for over a decade as a one-drug powerhouse centered on the hematology blockbuster Jakafi, the... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage
Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter and full-year 2025 financial results on February 6, 2026, signaling a definitive shift from a legacy company plagued by patent cliffs to a leaner,... 
Via MarketMinute
Topics Intellectual Property
News headline image
The Era of the Titans: Q4 2025 Mega-Deal Surge and the 2026 Economic Map
As of February 6, 2026, the global financial landscape is still reverberating from a historic tectonic shift that occurred in the final months of last year. In the fourth quarter of 2025, the M&A... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Biogen (BIIB) Deep Dive: Navigating the Pivot from MS Giant to Neuro-Innovation Powerhouse
As of February 6, 2026, Biogen Inc. (NASDAQ: BIIB) stands at a critical crossroads in its nearly 50-year history. Once the undisputed titan of the Multiple Sclerosis (MS) market, the Cambridge-based... 
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
Arrowhead (ARWR) Q1 2026 Earnings Call Transcript ↗
Arrowhead (ARWR) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Novartis (NVS) Q3 2024 Earnings Call Transcript ↗
Novartis (NVS) Q3 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Novartis Faces Biggest Patent Expiry Ever but Sees Growth Ahead ↗
Novartis AG (NVS) reported Q4 2025 results, with net sales up 1% to $13.34B, missing estimates. Generic competition and pricing impacted sales. 
Via Benzinga
Topics Intellectual Property
News headline image
Stock Market Today, Feb. 3: Novo Nordisk Slides as Pricing Pressure Clouds Obesity-Drug Outlook ↗
Novo Nordisk dropped after management forecasts weaker 2026 growth, shifting attention from recent results to pricing pressure and rising competition in obesity treatments. 
Via The Motley Fool
Topics Initial Public Offering Intellectual Property Stocks
News headline image
This Vanguard ETF Has Doubled the S&P 500's Returns Since the Start of 2025. Is It a Buy Now? ↗
It can be your key to a truly diversified portfolio. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Peering Into Novartis AG&#39;s Recent Short Interest ↗
 
Via Benzinga
News headline image
The Biological Singularity: How AlphaFold 3 Is Rewriting the Blueprint of Drug Discovery
As of early 2026, the promise of “digital-first” drug discovery has shifted from a speculative horizon to a tangible industrial reality. Since its groundbreaking release in May 2024, AlphaFold 3... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Even Near an All-Time High, This Dividend ETF Looks Extremely Cheap ↗
There are some bargains to be found for dividend investors right now. 
Via The Motley Fool
Topics ETFs
News headline image
The Biological Singularity: How Nobel-Winning AlphaFold 3 is Rewriting the Blueprint of Life
In the annals of scientific history, few moments represent a clearer "before and after" than the arrival of AlphaFold 3. Developed by Google DeepMind and its dedicated drug-discovery arm, Isomorphic... 
Via TokenRing AI
Topics Artificial Intelligence Economy
News headline image
Lilly Bolsters Immunology Arsenal with $1.2 Billion Acquisition of Ventyx Biosciences
In a strategic move to solidify its dominance in the burgeoning field of oral anti-inflammatories, Eli Lilly and Company (NYSE:LLY) announced on January 7, 2026, a definitive agreement to acquire... 
Via MarketMinute
< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.